Case Study: Selecting Frontline Therapy in Higher-Risk EGFR-Mutant NSCLC With Brain Metastases

This segment applies the preceding data to a higher-risk patient: a fit, newly diagnosed individual with a classic sensitizing mutation, a co-occurring high-risk alteration, high disease burden, and small asymptomatic brain metastases. The faculty agree that single-agent therapy would not be the preferred choice here and focus the decision on the combination strategies. They discuss how subtle subgroup signals, mutation subtype, co-mutation status, and biomarkers such as MET, might tip the balance, while acknowledging that either combination is defensible. A substantial portion addresses central nervous system disease: both combinations enhance already strong intracranial activity, focused radiosurgery is reserved for selected lesions, and whole-brain radiation should generally be avoided in this population. The panel closes with a practical monitoring approach for the chemotherapy combination, including early and frequent check-ins, laboratory surveillance, cytopenia management, and the transition to maintenance therapy, illustrating how the decision plays out in real practice.